TNGX Tango Therapeutics, Inc.
Healthcare$20.04-0.99%ClosedMarket Cap: $2.33B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
7.42
P/S
41.26
EV/EBITDA
-19.66
DCF Value
$-13.53
FCF Yield
-6.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.3%
Operating Margin
-206.2%
Net Margin
-188.2%
ROE
-41.5%
ROA
-24.6%
ROIC
-27.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-48.8M | $-45.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-41.9M | $-38.7M | $— | — |
| FY null | $62.4M | 96.3% | $-111.3M | $-101.6M | $— | — |
| Q3 null | $53.8M | 100.0% | $14.1M | $15.9M | $— | — |
| Q2 null | $3.2M | 80.4% | $-41.0M | $-38.9M | $— | — |
| Q1 null | $5.4M | 100.0% | $-42.5M | $-39.9M | $— | — |
| Q4 null | $4.1M | 100.0% | $-40.9M | $-37.7M | $— | — |
| FY null | $42.1M | 100.0% | $-145.6M | $-130.3M | $— | — |
| Q3 null | $11.6M | 100.0% | $-32.9M | $-29.2M | $— | — |
| Q2 null | $19.9M | 100.0% | $-29.6M | $-25.6M | $— | — |
| Q1 null | $6.5M | 100.0% | $-42.3M | $-37.9M | $— | — |
| Q4 2023 | $5.4M | 100.0% | $-35.0M | $-30.8M | $-0.32 | — |